Affinity Asset Advisors

Company

Related News

Apogee Therapeutics to Present Phase 2 APEX Part B Data as Fund Lifts Stake to $93 Million

May 27, 2026

Apogee Therapeutics will present Phase 2 APEX Part B data for zumilokibart on May 27, 2026. Affinity Asset Advisors increased its stake to 1.23 million shares valued at $93.21 million. The stock rose 86.9% over the past year.

Praxis Precision Medicines Submits Two NDAs, Reports $926M Cash Position

Dec 30, 2025

Praxis Precision Medicines has submitted new drug applications for ulixacaltamide in essential tremor and relutrigine in rare epilepsies, both granted Breakthrough Therapy Designation. The company reported $926 million in cash as of December 31, 2025.